It has been reported or the first time that a new Japanese experimental drug meant to treat Ebola has shown encouraging results for people participating in a study. Called Avigan or favipiravir, the drug is developed by Toyama Chemical, a subsidiary of Japan’s Fujifilm.
The drug interferes with the ability of the virus to copy itself. Approved as an influenza treatment in Japan last year, the drug was generally well tolerated. The drug is being tested in Guinea, one of the three West African countries worst hit by the Ebola epidemic.